<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04790188</url>
  </required_header>
  <id_info>
    <org_study_id>NOCOPE project</org_study_id>
    <nct_id>NCT04790188</nct_id>
  </id_info>
  <brief_title>Effect of a Nootropic on the Cognitive Performance in Young Adults</brief_title>
  <official_title>Effect of a Nootropic on the Cognitive Performance in Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Granada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad de Granada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to determine the effect of a nootropic on cognitive performance&#xD;
      (i.e., reaction time, inhibitory control, cognitive flexibility, working memory,&#xD;
      neuro-psychological outcomes).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cognitive decline is a worrisome consequence of normal or pathologic ageing, having a high&#xD;
      personal, eco- nomic and societal burden; also, it could herald the onset of dementia which&#xD;
      is associated with significant morbidity and mortality.&#xD;
&#xD;
      However, with a general increase in life expectancy and a corresponding increase in the&#xD;
      prevalence of age-related cognitive impairment, there have been concerted efforts towards the&#xD;
      development and adoption of preventive strategies that would minimize the risk of developing&#xD;
      dementia, or reduce the rate of cognitive decline with ageing. In the last few decades,&#xD;
      certain compounds have been found useful in the management of cognitive decline.&#xD;
&#xD;
      The term 'nootropic' has been used to define such substances with the capacity to enhance&#xD;
      cognition. While research has led to the synthesis of several drugs with nootropic effects,&#xD;
      attention is now being shifted to the discovery, characterization and utilization of&#xD;
      nootropics from natural sources for the prevention and management of age-related cognitive&#xD;
      decline.&#xD;
&#xD;
      25 young adults will be randomized into two conditions (nootropic and placebo conditions)&#xD;
      with 48 hours of separation between conditions. 48h previous to the randomization the&#xD;
      participants will perform a familiarization to avoid the learning effects.&#xD;
&#xD;
      Each evaluation day will conform to the following tests:&#xD;
&#xD;
        -  Simple and multiple reaction time&#xD;
&#xD;
        -  Inhibitory control&#xD;
&#xD;
        -  Cognitive flexibility&#xD;
&#xD;
        -  Working memory&#xD;
&#xD;
        -  Creative intelligence&#xD;
&#xD;
        -  Verbal fluidity&#xD;
&#xD;
        -  Motivation&#xD;
&#xD;
        -  Mood&#xD;
&#xD;
        -  Positive and negative emotions&#xD;
&#xD;
        -  Adverse effects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Simple and multiple reaction time</measure>
    <time_frame>1.5 hours</time_frame>
    <description>Vienna Test System®</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inhibitory control</measure>
    <time_frame>1.5 hours</time_frame>
    <description>Stroop test, E-Prime® software</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Working Memory</measure>
    <time_frame>1.5 hours</time_frame>
    <description>Tests Flankers and Task switching, EPrime ® software</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Working memory</measure>
    <time_frame>1.5 hours</time_frame>
    <description>N-Back y Spatial working memory , EPrime ® software</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creative Intelligence</measure>
    <time_frame>1.5 hours</time_frame>
    <description>CREA test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal fluidity</measure>
    <time_frame>1.5 hours</time_frame>
    <description>Phonological and semantic verbal fluidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motivation</measure>
    <time_frame>1.5 hours</time_frame>
    <description>Situational Motivation Scale (EMSI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>1.5 hours</time_frame>
    <description>EVEA scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and negative emotions</measure>
    <time_frame>1.5 hours</time_frame>
    <description>PANAS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>1.5 hours</time_frame>
    <description>Visual analogue scales of adverse effects (gastrointestinal, nervous or psychologic)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Cognitive Change</condition>
  <arm_group>
    <arm_group_label>Experimental intervention first.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive the nootropic first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental intervention second.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to receive the placebo first</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nootropic</intervention_name>
    <description>10g of Evo-Gamers® lemon flavor (HSN®). The nutritional composition per service is: L-Tyrosine (1000mg), Acetyl L-Carnitine HCL (500mg), Citicoline sodium (200mg), L-alpha-Glycerylphosphorylcholine (Alpha-GPC; 100mg), Vitamin C (150mg), Vitamin E (12.1mg), Vitamin B6 (3mg), Vitamin B2 (3mg), Vitamin A (810μg), Vitamin D (10μg), Vitamin B12 (5μg), Taurine (500mg), Caffeine (300mg), L-Theanine (150mg), Mango Leaves (2000mg), Huperzia Leaves (200mg). The dose to be administered is that recommended on the labeling and nutritional information of the nootropic which has been produced under GMP procedures and approved by the EFSA.</description>
    <arm_group_label>Experimental intervention first.</arm_group_label>
    <arm_group_label>Experimental intervention second.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10g of maltodextrin lemon flavor (HSN®).</description>
    <arm_group_label>Experimental intervention first.</arm_group_label>
    <arm_group_label>Experimental intervention second.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female&#xD;
&#xD;
          -  Ages 18-30 years&#xD;
&#xD;
          -  BMI: 18-30.0 kg/m2&#xD;
&#xD;
          -  Stable weight over the last 3 months (body weight changes&lt;3kg)&#xD;
&#xD;
          -  Participant must be capable and willing to provide consent, understand exclusion&#xD;
             criteria, instructions and protocols.&#xD;
&#xD;
          -  To talk and to read Spanish fluently.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of neurological disease or mental disease.&#xD;
&#xD;
          -  History of cardiovascular disease&#xD;
&#xD;
          -  Diabetes or hypertension&#xD;
&#xD;
          -  Pregnant, planning to become pregnant, or breastfeeding&#xD;
&#xD;
          -  Have been treated previously or during the study period with neurological drugs.&#xD;
&#xD;
          -  Have been treated previously or during the study period with prescription drugs:&#xD;
             antihypertensive, lipid lowering, acid uric lowering, glucose lowering, beta blockers&#xD;
             or any drug that under the investigator's judged could influence the results.&#xD;
&#xD;
          -  Allergy/intolerance to any ingredient of the nootropic.&#xD;
&#xD;
          -  High caffeine consumes (&gt;300mg/day, or &gt;3 coffees/day).&#xD;
&#xD;
          -  Any non-controlled medical condition which could influence results or could be&#xD;
             worsened by the participation in the study.&#xD;
&#xD;
          -  Are deemed unsuitable by the investigator for any other reason, that prevent data&#xD;
             collection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lucas Jurado-Fasoli, PhD student</last_name>
    <phone>618375662</phone>
    <phone_ext>34</phone_ext>
    <email>juradofasoli@ugr.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonatan R. Ruiz, PhD</last_name>
    <email>ruizj@ugr.es</email>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Granada</investigator_affiliation>
    <investigator_full_name>Jonatan Ruiz Ruiz</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nootropic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

